5 Key Takeaways

• 1

  Primary prevention aspirin use among U.S. adults decreased from 23.5% to 17.2% following updated clinical guidelines.

• 2

  The decline in aspirin use was most significant among adults over 70 years old, dropping from 46.1% to 34.4%.

• 3

  Adults with low ASCVD risk (< 10%) showed a reduction in aspirin use from 16.5% to 10.8%.

• 4

  Disparities in aspirin use reduction were observed, with significant decreases among White and Hispanic populations.

• 5

  Secondary prevention aspirin use among patients with known ASCVD remained stable, with rates of 66.3% between 2021 and 2023.